PPAPiraeus Port Authority S.A.
40.95EUR0.00%Mkt Cap: 1.11B $P/E: 11.87

Piraeus Port Authority S.A., together with its subsidiaries, provides port services in Greece. It operates through Container Terminal; Consession Arrangement Pier II &III; Car Terminal; Coasting; Cruise; Ship repairing; …

HeadlineSourceTime
Older
ΕΕιδήσεις Πειραιά
Ηη ναυτεμπορικη
Indicator.gr
Ηη ναυτεμπορικη
Indicator.gr
Ηη ναυτεμπορικη
Ηη ναυτεμπορικη
Ηη ναυτεμπορικη
ΕΕιδήσεις Πειραιά
maritimes.gr
Ηη ναυτεμπορικη
ΕΕιδήσεις Πειραιά
maritimes.gr
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters